COMPARATIVE EVALUATION OF MESENCHYMAL STEM CELLS DERIVED FROM BONE MARROW, ADIPOSE TISSUE, AND UMBILICAL CORD: IMPLICATIONS FOR IMMUNOMODULATORY THERAPIES

Mesenchymal stem cells (MSCs) are promising options for treating autoimmune and inflammatory disorders like rheumatoid arthritis. This is due to their ability to modulate immune responses, regenerate tissues, and release signaling molecules. However, MSCs from different tissue sources show significant differences in their behavior, which affects their clinical use. This review compares MSCs derived from bone marrow, adipose tissue, and umbilical cord, focusing on their isolation characteristics, morphology and immunophenotype, proliferation and aging, differentiation potential, immune-modulating ability, and paracrine and secretory profiles. Bone marrow-derived MSCs are the traditional and well-studied source. They demonstrate strong osteogenic differentiation and immune-modulating effects, but their clinical use is limited by the invasive collection process, variation due to donor age, and early aging during lab expansion. Adipose-derived MSCs provide higher cell yields and are easier to isolate. They strong adipogenic differentiation and regenerative activity, but their immune-suppressing strength and paracrine consistency can differ based on the donor’s metabolic state and inflammation levels. In contrast, umbilical cord-derived MSCs have better growth ability, delayed aging, stable appearance across passages, low immune response, and strong paracrine and immune-modulating characteristics. Overall, while all three MSC sources have therapeutic potential, umbilical cord-derived MSCs show better biological and immune-related traits for use in immune-related diseases. This comparison underscores the importance of selecting the right source to improve MSC-based treatments.